FDA Advisory Committee Raises Objections to Pfizer and Eli Lilly’s Tanezumab

FDA Advisory Committee Raises Objections to Pfizer and Eli Lilly’s Tanezumab

Source: 
BioSpace
snippet: 

Three days after U.S. Food and Drug Administration (FDA) staff raised safety concerns over Pfizer’s and Eli Lilly’s NGF osteoarthritis drug tanezumab, an advisory panel has also posted its own objections.